Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Collegium Pharmaceutical, the most common co-covered peer. Source depth averages 12 original sources per story, versus 4.7 across the same-window beat baseline.
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Collegium Pharmaceutical, the most common co-covered peer. Source depth averages 12 original sources per story, versus 4.7 across the same-window beat baseline. The 5 average consequence score is below the beat benchmark of 5.6 in the same window. We currently track 1 Healthcare story that mention Kymera Therapeutics, all published on February 26, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 41 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Kymera Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
The Q4 2025 earnings cycle for mid-cap healthcare highlights a strategic shift from clinical validation to commercial execution across gene editing, radiopharmaceuticals, and digital health. While platform innovators like Intellia and Kymera advance toward pivotal milestones, commercial leaders like Lantheus and Vericel are demonstrating the durability of high-barrier therapeutic markets.
Kymera Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
